NLM Digital Collections

Search

Start Over Subjects Antibodies, Monoclonal, Humanized -- therapeutic use ✖Remove constraint Subjects: Antibodies, Monoclonal, Humanized -- therapeutic use

1. Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, July 17, 2017
Subject(s):
Anabolic Agents -- therapeutic use
Antibodies, Monoclonal, Humanized -- therapeutic use
Osteoporosis, Postmenopausal -- drug therapy
Parathyroid Hormone-Related Protein -- therapeutic use
Anabolic Agents -- adverse effects
Anabolic Agents -- economics
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Bone Density Conservation Agents -- adverse effects
Bone Density Conservation Agents -- economics
Bone Density Conservation Agents -- therapeutic use
Comparative Effectiveness Research
Diphosphonates -- adverse effects
Diphosphonates -- economics
Diphosphonates -- therapeutic use
Osteoporotic Fractures -- prevention & control
Parathyroid Hormone-Related Protein -- adverse effects
Parathyroid Hormone-Related Protein -- economics
Randomized Controlled Trials as Topic
Teriparatide -- adverse effects
Teriparatide -- economics
Teriparatide -- therapeutic use
Humans
United States

2. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):
Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Complement C1 Inhibitor Protein -- adverse effects
Complement C1 Inhibitor Protein -- economics
Cost-Benefit Analysis
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

3. Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity

Author(s):
Kolbe, Allison, author
Publication:
Washington, DC : Office of the Assistant Secretary for Planning and Evaluation, Office of Science & Data Policy, December 2021
Subject(s):
Antibodies, Monoclonal, Humanized -- therapeutic use
COVID-19 Drug Treatment
Healthcare Disparities
Social Vulnerability
Urban Population
Vulnerable Populations
United States

4. Tezepelumab for severe asthma: final report

Author(s):
Rind, David M., author
Campbell, Jonathan D., author
Herce-Hagiwara, Belén, author
Herron-Smith, Serina, author
Fluetsch, Noemi, author
Pearson, Steven D., author
McQueen, R. Brett, author
Gutierrez, Eric, (Of University of Colorado), author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 13, 2023
Subject(s):
Antibodies, Monoclonal, Humanized -- therapeutic use
Asthma -- drug therapy
United States